We report the occurrence of skin toxicities in pediatric oncology patients on concomitant treatment with voriconazole and methotrexate (MTX). Of 23 patients who received this combination, 11 patients suffered from cheilitis and/or photosensitivity. In contrast, only in 1 of 9 patients who received voriconazole without MTX was photosensitivity observed. A mechanism of action was not able to be identified. We describe two cases with severe skin toxicities. Caution is warranted when using voriconazole and concomitant MTX.
D
ue to an increased risk of fungal exposure (specifically Aspergillus) caused by unavoidable construction activities in our hospital, immunocompromised pediatric patients treated for hematologic malignancies and autologous stem cell transplantation recipients received antifungal prophylaxis with oral voriconazole Strikingly, during the time period of this prophylaxis, increased incidence and severity of skin toxicities were observed in patients treated concomitantly with high-(HD) or low-dose (LD) methotrexate (MTX). This drew our attention, since antifungal prophylaxis with voriconazole was generally not used prior to the construction activities and the nature of skin lesions appeared to be different from that of the typical skin reactions induced by only methotrexate in these patients (1) (2) (3) .
Therefore, we have performed a systematic chart review in all patients treated with prophylactic voriconazole as recorded in the electronic hospital medication registration database within a period of 6 months (January 2011 to June 2011). Toxicities (photosensitivity and cheilitis) were graded according to CTCAE criteria (v4.0) (4). To illustrate our observations, we have described the observed toxicity for two patients in more detail.
A total of 32 patients received antifungal prophylaxis with voriconazole, most of whom were treated for acute lymphoblastic leukemia (ALL). In 23 of these patients (17 males, 6 females; 0 to 17 years old; median, 10 years of age), MTX was concomitantly administered as part of their treatment. An overview of all included patients is provided in Table 1 . In 11 of 23 patients (48%) receiving prophylactic voriconazole and concomitant MTX, skin toxicities were observed. All of these patients (9 male, 2 female) experienced photosensitivity (grade 1 to 3), whereas 6 patients also experienced cheilitis (grade 2 to 3). In contrast, in patients receiving voriconazole treatment without concomitant MTX, only 1 of 8 patients experienced a skin reaction (photosensitivity grade 3) and no patient experienced cheilitis.
The skin reactions most often erupted within a short time period after MTX treatment was given concomitantly (median time after the start of voriconazole, 36 days; range, 5 to 94 days) and typically presented as a painful erythema on sun-exposed areas of hands, face, and neck and with evolution of crustae on the lips. Mucositis, which is a typical high-dose-MTX-associated toxicity, was generally not observed in these patients during the observation period. Some skin reactions of photosensitivity grade 2 and higher were treated with topical hydrocortisone together with Vaseline gauzes, albeit without clear immediate improvement.
Skin toxicities were observed in both patients treated with voriconazole and concomitant HD MTX (3,000 mg/m 2 to 5,000 mg/ m 2 ) and patients treated with concomitant LD MTX (20 mg/m 2 to 30 mg/m 2 per week). No toxicity difference between LD and HD MTX treatments was apparent. MTX trough levels at 48 h were determined in all HD MTX patients as part of routine clinical care, and these were within expected ranges (0.00 to 5.00 mol/liter). In a few patients, 12-h voriconazole trough levels were determined to exclude a high-exposure causative for the observed severe and long-lasting skin toxicity, but these levels were also within normal limits (Table 1) . No other concomitant medications that could possibly be related to the observed skin toxicities were identified.
We performed a Wilcoxon signed-rank test to evaluate the location shift in the (ordinal) toxicity response grading between the two treatment groups. We compared cheilitis, photosensitivity, and the highest toxicity score (either cheilitis or photosensitivity) reached in each patient, but none of the comparisons resulted in a statistically significant difference (P Ͻ 0.05), a finding which is most likely related to the very small cohort of patients evaluated in this report. Unfortunately, we were not able to include additional patients since the construction activities with associated voriconazole use were finalized.
We assessed whether a dose-response relationship for MTX was able to be identified in the patients treated with both voriconazole and MTX, using a linear regression analysis with the type of MTX dose administered (intrathecal [i.t.], LD MTX, HD MTX) as a covariate and the toxicity grade as an outcome variable. For both cheilitis and photosensitivity grades, the coefficients were not significant (P Ͼ 0.05). However, when assessing the estimates, the coefficient for i. . In conclusion, again related to the limited sample size, no significant exposure-response relationship was able to be identified, although it was apparent that i.t. MTX, with expected substantially lower systemic exposure (5, 6) , reduced the grade of toxicity that may be experienced.
For two cases, we have described the observed toxicities in more detail.
Case 1.
A 2-year-old boy diagnosed with common ALL started treatment according to the DCOG-ALL-10 protocol. At the same time, antifungal prophylaxis with voriconazole was started (Fig. 1A) .
At day 14 after the start of a second cycle of HD MTX (70 days after the start of voriconazole), he developed facial squamous erythema. This photosensitivity was initially mild (grade 1) but increased to a severe photosensitivity (grade 3), and shortly thereafter, cheilitis (grade 1) was also observed. The photosensitivity reaction was treated with topical hydrocortisone (Fig. 1B and C) .
After a symptom-free period of several days, the facial erythema reoccurred (photosensitivity grade 1). At that stage, he also received treatment with mitoxantrone, cytarabine, and oral cotrimoxazole. Shortly after the third cycle of HD MTX, 100 days after the start of voriconazole, the facial erythema again increased to photosensitivity grade 3 and persisted for 2 days, after which the patient recovered for the next 8 days (Fig. 1D) .
The patient tested negative for herpes simplex virus. A Naranjo score (7) of 4 indicated a possible adverse drug reaction.
Case 2. A 4-year-old boy with Down's syndrome and pre-B-ALL was treated according to the DCOG-ALL-10 protocol. At 0, 15, and 34 days after starting voriconazole, MTX was administered intrathecally (Fig. 1E) . At day 24, the patient developed cheilitis (grade 2), for which local application of Vaseline was started. Hereafter, the cheilitis persisted but decreased in severity (grade 1). During further treatment, a facial macular rash which was considered to be a side effect of cytarabine based on the onset of the skin reaction, i.e., unrelated to voriconazole or MTX, was seen. At day 64 from the start of voriconazole, another dose of intrathecal MTX was given, and 5 days later, he again developed grade 2 cheilitis. At day 90, shortly after an HD MTX cycle, severe photosensitivity (grade 2 to 3) was observed. The patient was subsequently admitted to the hospital for pain medication, hydration fluids, and local application of Vaseline ( Fig. 1F and G) . Voriconazole prophylaxis was terminated. The photosensitivity reaction disappeared gradually over 1 week, whereas the cheilitis persisted for another week. A Naranjo score (7) of 4 indicated a possible adverse drug reaction. Skin reactions (reported incidence of 17 to 20%) and photosensitivity are major side effects of voriconazole treatment (8, 9) . They typically present as erythema of the skin and/or lips (i.e., cheilitis). Voriconazole skin toxicities do not correlate with voriconazole serum levels (10) . The nature of the skin lesions we observed appeared to be highly characteristic of voriconazole skin toxicity. However, the time frame at which the skin reactions developed after starting voriconazole with concomitant MTX in our patients was much shorter (median, 36 days) than the reporting time frame in which toxicity can develop during voriconazole monotherapy (generally Ͼ3 months) (11) .
Although MTX has been reported to cause mucositis, photosensitivity, and acral erythema in children receiving high-dose MTX treatment in some cases (12, 13) , the observed skin reactions in our patient cohort were not characteristic for most frequently seen MTX skin toxicities. Moreover, the cheilitis was not associated with any mucositis, which is a frequently observed adverse effect of MTX. However, as MTX by itself may also potentially induce photosensitivity, and considering that we were not able to include a control cohort of patients who received methotrexate only without voriconazole in this study, the precise contribution of MTX to the observed toxicities was not able to be fully elucidated and is therefore a limitation of this analysis. Nonetheless, overall, our findings do seem to indicate that the observed toxicities are not induced primarily by MTX itself.
For etiology, a pharmacokinetic interaction was considered unlikely. Voriconazole is metabolized by hepatic cytochrome P450 and subsequently eliminated into the bile (14) . It is an inhibitor of CYP2C19, CYP3A4, and CYP2C9 (14) . MTX, however, is converted by aldehyde oxidase to the toxic metabolite 7-OH-MTX and is mainly eliminated renally (15) , also confirmed by the low concentrations of both MTX and voriconazole trough levels.
No previous reports about interaction between voriconazole and MTX leading to skin toxicity have been published. A potential pathophysiological mechanism may be related to interference with the folate metabolism pathway, since some cases of photosensitivity reactions after the use of folate pathway-interfering agents have been reported previously (16) (17) (18) (19) . Alternatively, inhi- bition of the folate transporter RFC1 may be considered, but we did not find any literature supporting this hypothesis.
A wide range of MTX doses was given, but a consistent doseeffect relationship for the observed toxicities was not apparent, although it seemed that intrathecal MTX is associated with a reduced risk for toxicities. Clearly, this analysis was also limited by the number of included patients in the regression analysis.
Concomitant use of voriconazole and MTX can potentially lead to severe skin reactions. Although we have discussed a number of potential hypotheses, a mechanism of action for this apparent pharmacodynamic interaction effect remains inconclusive.
Based on the clear increase of observed skin toxicities during the use of this combination, concomitant use of voriconazole and MTX in children might better be discouraged. If, however, toxicities might occur, interruption or termination of voriconazole treatment should be considered while weighing the risks of interrupting antifungal prophylaxis.
